- Previous Close
15,800.00 - Open
15,600.00 - Bid 15,690.00 x --
- Ask 15,760.00 x --
- Day's Range
15,600.00 - 15,990.00 - 52 Week Range
13,350.00 - 22,150.00 - Volume
87,655 - Avg. Volume
168,954 - Market Cap (intraday)
346.348B - Beta (5Y Monthly) -0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield 200.00 (1.22%)
- Ex-Dividend Date Mar 29, 2024
- 1y Target Est
24,500.00
Boditech Med Inc. offers instruments and diagnostic reagents in South Korea and internationally. The company offers instruments, including ichroma II, diagnostic immuno-analyzer to measure the presence of various biomarkers for cardiac, cancer, hormones, infectious diseases, autoimmune diseases, and metabolic diseases; ichroma III, a high-throughput immuno-analyzer that enables simultaneous testing for various parameters; ExAmplar, a compact real time PCR that detects virus/bacteria quantitatively or qualitatively using ready-to-use cartridges; ichroma-50, an automated immunoassay system with high-throughput; Hemochroma PLUS, a handheld device that can run tests for anemia; portable analyzers ichroma M3 and ichroma M2; and NuActor, an automated nucleic acid extraction system. It also provides compact immunoassay analyzers, including AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10; cardiac reagents; cancer reagents; COVID-19 reagents; diagnostic reagents; reagents for hormones, infections, autoimmune, organ functions, molecular diagnostics, therapeutic drug monitoring, and other test items. In addition, the company offers Ichroma TRIAS, ultra-high sensitivity respiratory disease diagnostic equipment; ALFIAS-3, a diagnostic equipment; and SyncNeb. Boditech Med Inc. was founded in 1998 and is headquartered in Chuncheon-si, South Korea.
www.boditech.co.kr/enRecent News: 206640.KQ
View MorePerformance Overview: 206640.KQ
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 206640.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 206640.KQ
View MoreValuation Measures
Market Cap
347.23B
Enterprise Value
287.51B
Trailing P/E
11.40
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.49
Price/Book (mrq)
1.67
Enterprise Value/Revenue
2.07
Enterprise Value/EBITDA
6.50
Financial Highlights
Profitability and Income Statement
Profit Margin
19.62%
Return on Assets (ttm)
8.42%
Return on Equity (ttm)
14.57%
Revenue (ttm)
137.84B
Net Income Avi to Common (ttm)
27.05B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
66.62B
Total Debt/Equity (mrq)
3.87%
Levered Free Cash Flow (ttm)
19.17B